WGS

WGS

USD

GeneDx Holdings Corp. Class A Common Stock

$139.485+4.575 (3.391%)

Prix en Temps Réel

Healthcare
Diagnostics & Research
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$134.910

Haut

$141.750

Bas

$134.000

Volume

0.68M

Fondamentaux de l'Entreprise

Capitalisation Boursière

4.0B

Industrie

Diagnostics & Research

Pays

United States

Statistiques de Trading

Volume Moyen

0.58M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $55.17Actuel $139.485Haut $146

Actualités Connexes

Analyst Upgrades

Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140

Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings with a Equal-Weight and raises the price target from $95 to $140.

Voir plus
Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140
Analyst Upgrades

Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings with a Buy and raises the price target from $155 to $160.

Voir plus
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160
Analyst Upgrades

Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings with a Buy and raises the price target from $115 to $170.

Voir plus
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170
Analyst Upgrades

BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165

BTIG analyst Mark Massaro maintains GeneDx Holdings with a Buy and raises the price target from $140 to $165.

Voir plus
BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165
BusinessWire

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume growth to 33% year-over-year Expanded adjusted gross

Voir plus
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
PR Newswire

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating...

Analyst Upgrades

BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $140

BTIG analyst Mark Massaro maintains GeneDx Holdings with a Buy and raises the price target from $125 to $140.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.